Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE) Chatbot or Standard of Care Trial for Genetic Cancer Counseling, New York and Utah, 2020-2023 (ICPSR 39256)

Version Date: Feb 20, 2025 View help for published

Principal Investigator(s): View help for Principal Investigator(s)
Kimberly A. Kaphingst, University of Utah

https://doi.org/10.3886/ICPSR39256.v1

Version V1

Slide tabs to view more

The Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE) randomized controlled trial included 3,073 eligible patients between 2020-2023. The trial examined whether chatbot and standard of care approaches are equivalent in completion of pre-test cancer genetic services and genetic testing.

Kaphingst, Kimberly A. Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE) Chatbot or Standard of Care Trial for Genetic Cancer Counseling, New York and Utah, 2020-2023. Inter-university Consortium for Political and Social Research [distributor], 2025-02-20. https://doi.org/10.3886/ICPSR39256.v1

Export Citation:

  • RIS (generic format for RefWorks, EndNote, etc.)
  • EndNote
United States Department of Health and Human Services. National Institutes of Health. National Cancer Institute (U01CA232826)

university

Inter-university Consortium for Political and Social Research
Hide

2020-01-01 -- 2023-12-31
2020-01-01 -- 2023-12-31
  1. This collection is related to Broadening the Reach, Impact, and Delivery of Genetic Services (BRIDGE) Family History Interviews, New York and Utah, 2021, ICPSR 38831. For similar study information and characteristics, please refer to both studies.
Hide

The purpose of this study is to compare patients use of chatbot or standard of care approaches for genetic cancer testing.

3,073 patients from New York State and Utah were selected from a population health registry for a randomized controlled trial. The trial was conducted at the University of Utah Health and NYU Langone Health.

From 2020-2023, patients were given counseling for pre-test hereditary cancer from either a chatbot or standard of care. Focus was on if patients had started and completed genetic cancer services, or requested for genetic cancer testing. Some sociodemographic variables such as age, gender, and urbanicity was recorded.

Random samples of 2,241 patients at University of Utah Health and 3,061 at NYU Langone Health were selected from a population health registry.

Cross-sectional

Trial participants were aged 25 to 60 years, had a primary care visit in the previous 3 years, eligible for cancer genetic evaluation, English or Spanish speaking, no prior cancer diagnosis other than non-melanoma skin cancer, no prior cancer genetic counseling or testing, and had an electronic patient portal account.

Individual

The data includes variables about participants' use of genetic cancer counseling by chatbot or standard of care approaches. There are geographic variables (state) and demographic variables (age, gender, urbanicity, and language).

1,629 patients from New York State and 1,444 patients from Utah participated in the study.

Hide

2025-02-20

Hide

Notes